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Summary
Background Patients with psoriasis are often concerned about the risk of serious
infection associated with systemic psoriasis treatments.
Objectives To develop and externally validate a prediction model for serious infec-
tion in patients with psoriasis within 1 year of starting systemic therapies.
Methods The risk prediction model was developed using the British Association of
Dermatologists Biologic Interventions Register (BADBIR), and the German Psoria-
sis Registry PsoBest was used as the validation dataset. Model discrimination and
calibration were assessed internally and externally using the C-statistic, the cali-
bration slope and the calibration in the large.
Results Overall 175 (17%) out of 10 033 participants from BADBIR and 41
(17%) out of 2423 participants from PsoBest developed a serious infection
within 1 year of therapy initiation. Selected predictors in a multiple logistic
regression model included nine baseline covariates, and starting infliximab was
the strongest predictor. Evaluation of model performance showed a bootstrap
optimism-corrected C-statistic of 064 [95% confidence interval (CI) 060–069],
calibration in the large of 002 (95% CI 014 to 017) and a calibration slope
of 088 (95% CI 070–107), while external validation performance was poor,
with C-statistic 052 (95% CI 042–062), calibration in the large 006 (95% CI
025 to 037) and calibration slope 036 (95% CI 024 to 097).
Conclusions We present the first results of the development of a multivariable pre-
diction model. This model may help patients and dermatologists in the U.K. and
the Republic of Ireland to identify modifiable risk factors and inform therapy
choice in a shared decision-making process.
What’s already known about this topic?
• Patients and their clinicians are often concerned about the risk of serious infection
associated with biological therapies for the treatment of psoriasis.
• However, there are no current tools available to estimate an individual’s risk of
serious infection when starting a systemic therapy.
What does this study add?
• This study found that the serious infection risk prediction model had good calibra-
tion and moderate discrimination
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• The model included chronic obstructive pulmonary disease, alcohol intake, number
of comorbidities and employment status, in addition to age, sex, Psoriasis Area and
Severity Index, choice of starting therapy and body mass index.
• These are the first results of the multivariable prediction model, which may help
patients and dermatologists in the U.K. and the Republic of Ireland to identify
modifiable risk factors and inform therapy choice in a shared decision-making
process.
Given that the majority of systemic therapies for psoriasis
suppress the immune system, patients and their clinicians are
often concerned about an associated risk of serious infection.
Patients with psoriasis often experience comorbidity and
have lifestyle factors that themselves may be associated
with a higher risk of serious infection than in the general
population.1
A recent study found that in patients who do receive sys-
temic therapies, 12% of patients practise intentional nonadher-
ence, where patients decide not to follow the prescribed
medication regimen.2 This may stem from concerns about
potential negative effects of treatment such as the associated
risk of infection or other serious adverse events. It could lead
to a missed opportunity of achieving a good clinical outcome,
in turn impacting on the achievable quality of life for the
patient. Addressing patient concerns about the risk of serious
infection associated with systemic therapies is, therefore, a
vital aspect of any consultation prior to initiating such thera-
pies. To our knowledge, there are no tools available to help
patients with psoriasis or their clinicians to estimate the risk
of serious infection when starting a systemic therapy.
Our objective was to develop a multivariable prediction
model for serious infection within 1 year of systemic therapy
initiation in patients with psoriasis. Within the European Net-
work of Centres for Pharmacoepidemiology and Pharmacovigi-
lance network of psoriasis registries (www.psonet.eu), we
used a national, prospective psoriasis registry to develop and
test the internal validity of the model [the British Association
of Dermatologists Biologic Interventions Register (BADBIR)].
We then applied the model to a second national, prospective
psoriasis registry (PsoBest, Germany) to test the external valid-
ity. Such a model would enable the dermatologist and patient
to determine a personalized risk of first serious infection
within 1 year of systemic therapy initiation.
Patients and methods
Data sources and study population
Data from BADBIR3 were used to develop the serious infection
risk prediction model. To test whether this risk prediction
model was generalizable to other populations, external valida-
tion using a cohort from the German Psoriasis Registry PsoB-
est4 was performed. The structures of these two registries are
very similar.
Development cohort (U.K. and Republic of Ireland)
BADBIR is a large, ongoing, prospective pharmacovigilance
registry of patients with psoriasis. It was established in
2007 in the U.K. and Ireland to compare the safety of bio-
logical therapies against nonbiological systemic therapies. In
total 153 secondary-care dermatology centres in the U.K.
and Ireland have contributed to the registry in this data
snapshot. Patients with a Psoriasis Area and Severity Index
(PASI) ≥ 10 and Dermatology Life Quality Index
(DLQI) > 10 initiating a systemic biological or nonbiological
medication are eligible for inclusion in the register. In Eng-
land, the National Institute for Health and Care Excellence
(NICE) recommends that all patients with psoriasis on bio-
logical therapies should be registered on BADBIR. Data are
collected 6 monthly for the first 3 years, then annually
thereafter. Detailed assessments at baseline and follow-up
have been performed. A data snapshot from February 2017
was used in the development dataset.
Validation cohort (Germany)
The German Psoriasis Registry PsoBest is a national prospective
patient registry established in 2008. In total 865 dermatology
practices (n = 797) and clinics (n = 68) are registered in
PsoBest from across Germany.4 Detailed assessments at base-
line and follow-up are also performed, similarly to those with
BADBIR.5 A data snapshot from June 2017 was used as the
validation dataset.
Data analysis
Eligible criteria from both BADBIR and PsoBest include
patients with chronic plaque psoriasis starting either a licensed
biological therapy for psoriasis – for example etanercept
(Enbrel), adalimumab (Humira), ustekinumab (Stelara) and
infliximab (Remicade) – and patients starting acitretin, pso-
ralen–ultraviolet A, ciclosporin, fumaric acid esters,
methotrexate and hydroxycarbamide.
Patients in both cohorts contributed to the study if they had
a follow-up period of 1 year or more, or had < 1 year of fol-
low-up but developed one or more serious infections within
the follow-up period. Follow-up was measured from the first
prescribed dose of the first therapy while registered in either
cohort.
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In BADBIR we defined serious infection as any infection
that was associated with or prolonged hospitalization, required
intravenous antimicrobial therapy or led to death.6 A similar
definition was used for serious infections in the PsoBest reg-
istry, but it was not possible to include the use of intravenous
antimicrobial therapy in the definition. Four additional cases
were included from BADBIR based only on the use of intra-
venous antimicrobial therapy. We limited the outcome to hav-
ing had one or more serious infections within the first year.
Prior to model development, we performed descriptive analy-
sis of the baseline covariates in both cohorts.
Model development
Baseline predictor covariates were identified a priori from con-
sensus in the BADBIR research analysis group and a literature
review.7 A two-tier predictor selection process was performed.
The first tier identified covariates that were highly likely
important factors for the development of serious infections.
These covariates were age, sex, PASI, choice of starting ther-
apy and body mass index (BMI) at baseline. The nearest PASI
score within 6 months of the date of therapy initiation was
eligible for inclusion.
Regardless of the bivariate analysis results, these covariates
were included in the final multiple logistic regression model.
The second tier identified covariates that were probable
important factors for the development of serious infections.
These covariates were alcohol intake per week, cigarettes
smoked per day, chronic obstructive pulmonary disease
(COPD), asthma, depression, diabetes, hypertension, employ-
ment status, number of comorbidities, presence of psoriatic
arthritis, total number of previous biological therapies, and
total number of previous nonbiological systemic treatments.
The number of comorbidities denoted the patient’s self-identi-
fied list of comorbidities. Employment status was divided into
three categories as previously defined:8 (i) those working full
time, part time or full time in the home, or who were stu-
dents; (ii) those who were unemployed but seeking work or
not working due to disability or ill health; and (iii) those
who were retired.
The information for the predictors was captured from
patient-reported baseline questionnaires and clinician-com-
pleted questionnaires. As we included only variables available
to the clinicians at baseline prior to initiation of therapy, we
did not include time-varying factors such as switching of ther-
apy or use of concomitant or combination systemic therapies.
For this list of predictors a ratio of 10 events per predictor
variable was achieved.
The outcome of serious infection within 1 year of treatment
initiation was treated as a binary outcome, with values of 0
for no infection and 1 for at least one infection within 1 year.
Bivariate logistic regression models were performed to obtain
unadjusted odds ratios. The second-tier potential predictors
were assessed for inclusion using backward elimination in a
logistic regression model, with a P-value of 01 as the cut-off.
The equation for the prediction of serious infection was pro-
duced from the resulting multiple logistic regression model.
Internal validation
The model’s discriminative performance was assessed by the
concordance statistic (C-statistic, equivalent to the area under
the receiver operating characteristic curve), representing the
probability that the model would identify patients having had
a serious infection in the 1 year as having a higher predicted
risk than patients without such an event. The model calibra-
tion was assessed using the calibration slope and the calibra-
tion in the large (CITL). CITL measures whether the predicted
prevalence was less than (CITL < 0) or greater than the
observed prevalence (CITL > 0). The calibration slope primar-
ily detects whether the model is overfitted (slope < 1).9 Inter-
nal validation was performed on the prediction model; the
statistical details are presented in Appendix S1 (see Supporting
Information).
External validation
The final risk prediction model, after adjustment for overfit-
ting, was applied to each participant in the external validation
cohort. The performance of the model was similarly assessed
by the C-statistic (discrimination), the calibration slope and
the CITL (calibration).
All analyses were performed using Stata version 151 (Stata-
Corp, College Station, TX, U.S.A.). The study was conducted
and reported according to the Transparent Reporting of a mul-
tivariate prediction model for Individual Prediction Or Diag-
nosis (TRIPOD) guidelines.10
Ethical approval
BADBIR was approved in March 2007 by the National Health
Service Research Ethics Committee North West England, refer-
ence 07/MRE08/9. All patients gave written informed consent
for their participation in the registry. Approval for PsoBest was
obtained in July 2007 from the ethics commission of the State
Medical Association Hamburg (no. 2805).
Results
In the development cohort from BADBIR, 10 033 patients
were eligible for inclusion. In the validation cohort from
PsoBest, 2423 patients were eligible for inclusion (Fig. 1).
Table S1 (see Supporting Information) summarizes the back-
ground characteristics of the two registry populations. Broadly,
patients from PsoBest were older and more likely to be current
smokers, drink more alcohol, be currently working and have
less comorbidity, but were less likely to have a BMI > 30 kg
m2 or depression. Regarding treatment, patients from PsoBest
were more likely to receive nonbiological options and less
likely to receive biological options.
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Model development, performance and validation
From BADBIR, 175 patients (17%) developed a serious infec-
tion within 1 year of starting systemic therapy. The location
types of serious infections in both cohorts as coded by the
High-Level Term in the Medical Dictionary for Regulatory
Activities are presented in Table 1, and the associations
between the baseline covariates and serious infection in bivari-
ate models are presented in Table S2 (see Supporting Informa-
tion). In the multiple logistic regression backward selection
model, the variables of COPD, alcohol intake, number of
comorbidities and employment status were selected in addi-
tion to age, sex, PASI, choice of starting therapy and BMI
(Table 2). The apparent and internal validation performance
statistics of the final multivariable model are presented in
Table 3.
The optimism-adjusted model discrimination gave a C-sta-
tistic of 064 [95% confidence interval (CI) 060–069], and
the optimism-adjusted model calibration gave a CITL of 0015
(95% CI 014 to 017) and a calibration slope of 088 (95%
CI 070–107). A uniform shrinkage factor of 087 (the cali-
bration slope of the test performance, Table 3) was applied to
the beta-coefficients of the multivariable model. The mean
predicted probability of serious infection within 1 year of ini-
tiating therapy after adjustment for overfitting was 0017 (SD
0014, range 0006–035).
As examples using the shrinked coefficients, if a 1% risk
cut-off was applied to identify serious infection, the sensitivity
of the test would be 903% and the specificity 169%. If a 2%
risk cut-off was applied to identify serious infection, the sensi-
tivity of the test would be 463% and the specificity would be
783%. The risk prediction equation for the log odds of the 1-
year serious infection risk is given in Appendix 2.
External validation
From PsoBest, 41 patients (17%) developed a serious infec-
tion within 1 year of starting systemic therapy. The perfor-
mance of the final risk prediction model in the PsoBest dataset
gave a C-statistic of 052 (95% CI 042–062), a CITL of 006
(95% CI 025 to 037) and a calibration slope of 036 (95%
CI 024 to 096). The mean predicted risk of serious infec-
tion within 1 year after systemic therapy initiation was 0016
(SD 0011, range 0006–018). Table S3 (see Supporting
Information) shows low relatedness between the BADBIR and
the PsoBest datasets. In an additional exploratory analysis,
hypertension was selected in addition to the other covariates
of the BADBIR prediction model as a strong predictor of 1-
year serious infection in the PsoBest cohort (Table S4; see
Supporting Information). The C-statistic of this exploratory
model was 067 (95% CI 059–075).
Discussion
We developed a multivariable model to predict the risk of
serious infection within 1 year of starting a systemic therapy
Fig 1. Flow diagram depicting the participant selection numbers of the development dataset (British Association of Dermatologists Biologic
Interventions Register, BADBIR) and the validation dataset (PsoBest).
© 2018 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists
British Journal of Dermatology (2019) 180, pp894–901
Risk prediction model for serious infections in psoriasis, Z.Z.N. Yiu et al. 897
in patients with moderate-to-severe psoriasis. To our knowl-
edge, this is the first study to use two large psoriasis treatment
registries to develop and validate externally for serious
infection after starting systemic therapy for psoriasis. How-
ever, the discriminative activity of the model after internal val-
idation and adjustment for optimism was not perfect, with a
C-statistic of 064. At this stage, we feel that this is the first in
several systematic steps in working towards a clinically appli-
cable model for predicting serious infection in patients with
psoriasis.
The strengths of this study are (i) the use of a large,
national, prospective registry representative of patients with
moderate-to-severe psoriasis in the real world to develop the
algorithm and (ii) detailed data capture allowing inclusion of
covariates that are clinically most relevant to the risk of infec-
tion for consideration in the model. The covariates included
are readily available in a clinical setting, and the risk predic-
tion score can be easily applied in the clinic.
The main limitation of the model was a C-statistic below
070. Thus, it is likely that factors or interactions between
variables that might be predictive of serious infection were
not included. For example, previous history of a serious infec-
tion was not captured consistently, we do not measure adher-
ence to medication, and geographical location may be
influential in the risk of serious infection. Due to the high
proportion of missing data, DLQI11 could not be included as a
covariate. There may be residual confounding from covariates
that were not known to be associated with the risk of serious
infection, for example from nonmedical domains such as
demographical factors, personal hygiene practices,
predisposing work conditions and other lifestyle factors, and
were therefore not included.
Another limitation is the low number of outcome events.
As sample size in prediction models is dictated by the number
of events per variable, the number of serious infection events
(175) restricted the number of covariates that could be
included in the model. This limits our ability to include other
variables that could potentially improve the discrimination of
the model.
We found statistically significant clinical covariates that were
predictors for serious infection in patients receiving systemic
therapies for psoriasis. Female patients had 35% higher odds
of developing a serious infection than male patients. This
result was unsurprising, given that we had previously reported
that female participants in the BADBIR cohort had a 79%
higher risk of discontinuing biological therapies due to an
adverse event.12
The total number of comorbidities, a proxy for patient
frailty, was also a significant predictor, and each additional
comorbidity was associated with an 8% higher odds of serious
infection. COPD was selected in the model as an important
comorbidity, associated with an odds ratio of 178 of serious
infection. This is because many patients are hospitalized for
treatment of infective exacerbations of COPD. Alcohol intake
was associated with a small but significant increase in the odds
of serious infection, with each unit per week associated with
an odds ratio of 101.
Although age was a covariate forced into the model, sur-
prisingly this was not a statistically significant predictor of
infection. This is likely due to the fact that working status,
which is a proxy of functional status and overall health, was
Table 1 Location types of serious infections as coded by the MedDRA
High-Level Terms in BADBIR and the equivalent numbers in PsoBest
BADBIR PsoBest
Lower respiratory tract and lung infections 73 (07) 5 (02)
Urinary tract infections 32 (03) < 5
Abdominal and gastrointestinal infections 15 (01) 9 (04)
Skin structures and soft-tissue infections 12 (01) < 5
Sepsis, bacteraemia, viraemia and fungaemia 11 (01) < 5
Upper respiratory tract infections 11 (01) 5 (02)
Ear infections 8 (01) < 5
Cardiac infections 6 (01) 0
Bone and joint infections 5 (0) 0
Female reproductive tract infections < 5 < 5
Male reproductive tract infections 0 < 5
Hepatobiliary and spleen infections < 5 < 5
Dental and oral soft-tissue infections 0 < 5
Muscle and soft-tissue infections 0 < 5
Eye and eyelid infections 0 < 5
Vascular infections 0 < 5
The data are the number (percentage proportion) of each type
of serious infection out of all participants; n-values < 5 are cen-
sored due to patient confidentiality. MedDRA, Medical Dictionary
for Regulatory Activities; BADBIR, British Association of Derma-
tologists Biologic Interventions Register.
Table 2 Final multivariable prediction model for risk of serious
infection 1 year after initiation of therapy in the development cohort
(British Association of Dermatologists Biologic Interventions Register)
Variable OR (95% CI)
Age 100 (098–101)
Female sex 135 (113–195)
Starting drug
Nonbiological systemics Reference
Etanercept 087 (054–140)
Infliximab 355 (203–621)
Adalimumab 110 (077–154)
Ustekinumab 130 (087–193)
PASI 101 (099–102)
Alcohol (units per week) 101 (100–102)
Number of comorbidities 108 (104–113)
COPD 178 (101–311)
Body mass index 101 (099–103)
Working status
Working Reference
Unemployed 142 (099–204)
Retired 205 (128–331)
PASI, Psoriasis Area and Severity Index; COPD, chronic obstruc-
tive pulmonary disease; OR, odds ratio; CI, confidence interval.
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also included and adjusted for in the model, with retired par-
ticipants associated with twice the odds of serious infection
than participants who were working. The predictor with the
highest strength of association with serious infection was
treatment with infliximab. In separate time-to-event analyses,
participants on infliximab in BADBIR13 and the Psoriasis Lon-
gitudinal Assessment and Registry, a large U.S.A.-based psoria-
sis registry,14 also found that infliximab was associated with a
higher risk of serious infection.
The BADBIR and PsoBest registry cohorts are substantially
different from each other (Table S4; see Supporting Informa-
tion). This difference is exemplified by the results of an addi-
tional exploratory analysis. We found that hypertension,
which was not significant in the BADBIR cohort, was strongly
predictive for serious infection in the PsoBest cohort. In addi-
tion, the odds ratios of working status, female sex, individual
treatments and the number of comorbidities were also very
different between the two models (Table S4).
There are several notable differences between the two reg-
istries. Firstly, there are differences in the proportions of
patients on nonbiological systemic therapies and biological
therapies (Table S1; see Supporting Information). Secondly,
patients in BADBIR on nonbiologics are predominantly using
methotrexate,15 while patients in PsoBest on nonbiologics are
predominantly using fumaric acid esters.16 In addition, inflix-
imab is only recommended to be used in the U.K. for patients
with very severe psoriasis (PASI ≥ 20, DLQI > 18). This intro-
duces confounding by indication that is not present in the
PsoBest population.
Both the heterogeneity of outcome frequency and poor
model transportability between the two different psoriasis reg-
istries are not surprising. A study by Psonet, a European col-
laboration of psoriasis registries, investigated the risk of
serious infection in patients receiving tumour necrosis factor
inhibitors with data from Italian (Psocare) and Spanish (BIO-
BADADERM) psoriasis registries and a healthcare database in
Israel (Clalit Health Service database).17 That study showed
marked heterogeneity in the infection rates between the indi-
vidual countries (I2 > 90%). The authors attributed this to
variation in the definition of what constituted a ‘serious’
infection, which is also likely to have contributed to differ-
ences between BADBIR and PsoBest.
The propensity to admit a patient into the hospital, a key
determinant of whether an infection is classed as ‘serious’,
varies between countries, and it is notable that all of the
BADBIR centres were from hospital clinics in secondary care,
in contrast to the participation of predominately individual
dermatology clinics and practices of primary care in PsoBest.
This difference in healthcare systems may also introduce con-
founding by indication. For example, individual practices in
primary care in Germany may be more reluctant to prescribe
infliximab given that it needs to be administered in a hospital
setting. It is possible that patients attending hospital clinics
may be more likely to be admitted directly into the hospital if
a serious infection was suspected compared with primary-care
clinics.
The risk prediction model would facilitate discussions
between the clinician and the patient regarding risk factors for
serious infection. As the interpretation of the risk of serious
infection and decision regarding treatment choice may reflect
the personal values of the patient, such a model could facili-
tate the shared decision-making process. However, it is not
possible to quantify the risk of serious infection precisely at
the present stage of model development.
In conclusion, we have developed a preliminary prediction
model for the risk of developing a serious infection within
1 year of initiation of systemic therapy in patients with psori-
asis. We envisage that such an algorithm could help clinicians
and the patient to choose the right starting therapy, discuss
lifestyle choices and identify risk-minimizing modifiable beha-
viours in shared decision making with their patients. Further
development of the model, for example the inclusion of other
predictors, and temporal validation using the U.K. and Ireland
population of patients in BADBIR, is warranted after further
data accrual.
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Appendix 2. Risk prediction model
The risk score from a logistic regression model to predict seri-
ous infection within 1 year of initiation of systemic therapy
for psoriasis:
Log odds of serious infection within 1 year =
4985364  (00042559 9 age) + (03036825 9 female
sex) + (00062117 9 PASI) + (00084999 9 units of alcohol
per week) + (00809034 9 number of comorbidities)
+ (05743102 9 COPD) + (00098085 9 BMI) +
(0354117 9 unemployed or not currently working)
+ (07202485 9 retired)  (0140139 9 etanercept) +
(1267439 9 infliximab) + (00975531 9 adalimumab) +
(02599529 9 ustekinumab).
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